^
9ms
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies (clinicaltrials.gov)
P1, N=60, Recruiting, BioEclipse Therapeutics | N=24 --> 60 | Trial completion date: Mar 2025 --> Oct 2026 | Trial primary completion date: Oct 2024 --> Aug 2025
Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • CRX100
over2years
Study of CRX100 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=24, Recruiting, BioEclipse Therapeutics | Trial completion date: May 2022 --> Mar 2025 | Trial primary completion date: May 2022 --> Oct 2024
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
CRX100
almost4years
Study of CRX100 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=24, Recruiting, BioEclipse Therapeutics | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
CRX100
4years
Study of CRX100 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=24, Not yet recruiting, BioEclipse Therapeutics | Initiation date: Jun 2020 --> Oct 2020
Clinical • Trial initiation date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
CRX100
over4years
Study of CRX100 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=24, Not yet recruiting, BioEclipse Therapeutics
Clinical • New P1 trial
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
CRX100